摘要: The causes of prostate cancer reflect a complex interaction between environmental and genetic factors. Improvement in screening has reduced the incidence cancer, risk assessment schemata have enhanced therapy, both for localized disease locally recurrent cancer. use hormone therapy been further evaluated, as primary advanced cancers, lymph node-positive de novo metastatic Modest inroads made treatment understanding androgen-independent Advances factors, environmental, associated with development progression cancer; screening; optimizing localized, recurrent, disease. This article reviews most salient observations reported November 1, 1997 October 31, 1998.
sci-hub.st 参考文章(77)
G D Chisholm, R F Deane, G B McKelvie, C D Rennie, E L Gilliland, C P Chilton, M G Royle, N H Townell, J Breakey, S M Cresswell, J Glaholm, G M Sole, J J Bolger, M J Stower, M H Ashken, D A Tolley, F J Bramble, P A Jones, R A Styles, Moffat Lef., R W Glashan, Rhind, A Radley, G J Fellows, J Crowther, B Hafner, S Knight, E Thompson, J Smith, J Burrett, P B Clark, J Boreham, R Peto, L N Jurczyk, B A DeSousa, S Parish, Logie Jrc., Ross Rta., Cox, K Perry, T P Stephenson, K K Sethia, Turner Dtl., M Davies, Harrison Gsm., G F Carswell, Rogers Acn., M Lucas, M R Heal, V Boag, J Hetherington, D Kirk, Charlton Cac., Shepheard Bgf., N A Green, M F Smith, T B Hargreave, Moore Kth., R J Morgan, K N Bullock, Bevis Cra., J B Anderson, A L Stewart, Newling Dwk., B Richards, Grayson Cea., Gaches Cgc., P T Doyle, Robinson Mrg., S Sagar, R J Shearer, C M Evans, R A Jones, Wightman Jak., E R Coulton, J C Smith, M E French, C S Powell, Fernie Cgm., Orr Pgg., M Claridge, Gallegos Crr., G H Urwin, G M Watson, C Roberts, S Griffin, M B Rose, M Fordham, G S Watson, W T Lawrence, R Pollard, P H Smith, M J James, Grant Jbp., J P Ward, R R Hall, M Hehir, J L Williams, R W Thomson, L L Beynon, R J Luck, R Rampling, R S Adib, P English, A McGregor, C D Baumber, J W Blaxland, M H Devereux, R Clack, Immediate versus deferred treatment for advanced prostatic cancer: Initial results of the Medical Research Council trial BJUI. ,vol. 79, pp. 235- 246 ,(1997)
Jeffrey M. Trent, Sarah D. Isaacs, G. Steven Bova, Deborah A. Meyers, Francis S. Collins, Patrick C. Walsh, Jianfeng Xu, Jeffrey R. Smith, Henrik Grönberg, Henrik Grönberg, Diha Freije, John D. Carpten, William B. Isaacs, Early Age at Diagnosis in Families Providing Evidence of Linkage to the Hereditary Prostate Cancer Locus (HPC1) on Chromosome 1 Cancer Research. ,vol. 57, pp. 4707- 4709 ,(1997)
Robert W. Haile, Lawrence N. Kolonel, Brian E. Henderson, Gerhard A. Coetzee, Ronald K. Ross, Sue Ann Ingles, Wei Wang, Laura Crocitto, Association of prostate cancer with vitamin D receptor haplotypes in African-Americans. Cancer Research. ,vol. 58, pp. 1620- 1623 ,(1998)
Duncan B. McLaren, Michael McKenzie, Graeme Duncan, Tom Pickles, Watchful waiting or watchful progression Cancer. ,vol. 82, pp. 342- 348 ,(1998) , 10.1002/(SICI)1097-0142(19980115)82:2<349::AID-CNCR15>3.0.CO;2-Z
D P Wood, M Banerjee, Presence of circulating prostate cells in the bone marrow of patients undergoing radical prostatectomy is predictive of disease-free survival. Journal of Clinical Oncology. ,vol. 15, pp. 3451- 3457 ,(1997) , 10.1200/JCO.1997.15.12.3451
Norman J. Maitland, Michael Stower, Catherine A. Macintosh, Nick Reid, Precise Microdissection of Human Prostate Cancers Reveals Genotypic Heterogeneity Cancer Research. ,vol. 58, pp. 23- 28 ,(1998)
D J Bloomfield, M D Krahn, T Neogi, T Panzarella, T J Smith, P Warde, A R Willan, S Ernst, M J Moore, A Neville, I F Tannock, Economic evaluation of chemotherapy with mitoxantrone plus prednisone for symptomatic hormone-resistant prostate cancer: based on a Canadian randomized trial with palliative end points. Journal of Clinical Oncology. ,vol. 16, pp. 2272- 2279 ,(1998) , 10.1200/JCO.1998.16.6.2272
A V D'Amico, R Whittington, S B Malkowicz, D Schultz, I Kaplan, C J Beard, J E Tomaszewski, A A Renshaw, K R Loughlin, J P Richie, A Wein, Calculated prostate cancer volume greater than 4.0 cm3 identifies patients with localized prostate cancer who have a poor prognosis following radical prostatectomy or external-beam radiation therapy. Journal of Clinical Oncology. ,vol. 16, pp. 3094- 3100 ,(1998) , 10.1200/JCO.1998.16.9.3094
I F Tannock, D Osoba, M R Stockler, D S Ernst, A J Neville, M J Moore, G R Armitage, J J Wilson, P M Venner, C M Coppin, K C Murphy, Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. Journal of Clinical Oncology. ,vol. 14, pp. 1756- 1764 ,(1996) , 10.1200/JCO.1996.14.6.1756
D C Smith, R L Dunn, M S Strawderman, K J Pienta, Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer. Journal of Clinical Oncology. ,vol. 16, pp. 1835- 1843 ,(1998) , 10.1200/JCO.1998.16.5.1835